← Back to Home

Taladegib pulmonary fibrosis trial meets endpoints: Lung function and imaging show signs of improvement, with magnitude of benefit yet to be disclosed

Positive results from a Phase 2 trial involving 213 patients offer new clues for treating idiopathic pulmonary fibrosis. However, full data and further trials are needed to determine whether statistical success can translate into lasting, noticeable improvement.

By SURL BioNews

For patients with idiopathic pulmonary fibrosis (IPF), progressive scarring of the lungs can make breathing increasingly difficult. Treatment research therefore seeks not only to slow deterioration but also to identify ways to improve lung function. On October 8, Endeavor BioMedicines announced that its investigational drug taladegib met the primary and several key secondary endpoints in the Phase 2b WHISTLE-PF trial, providing a new clinical signal in that direction.

The randomized, double-blind, placebo-controlled trial enrolled 213 patients with IPF and evaluated different doses over 24 weeks of treatment. The company said 73% of participants were also receiving existing standard treatment. This means the results also address a practical question: whether the new drug can provide additional benefit on top of patients’ existing treatment.

The primary endpoint was the change in percent predicted forced vital capacity (ppFVC), which reflects the amount of air patients can expel during a forced exhalation as a proportion of the predicted normal value. According to the company’s announcement, the taladegib group showed a statistically significant difference compared with the placebo group at 24 weeks, as well as an increase from baseline. However, the announcement has not yet provided the magnitude of improvement, results for each dose, or confidence intervals, so the size of the benefit cannot be assessed at this stage.

Imaging results offer another layer of evidence. The company said quantitative analysis of high-resolution computed tomography showed improvements in measures including total lung volume and pulmonary fibrosis compared with placebo. The consistent direction of the lung function and imaging findings supports further investigation into whether the drug affects disease progression. However, changes in imaging measures alone are still insufficient to demonstrate that lung scarring has been durably reversed.

Taladegib, also known as ENV-101, targets the Hedgehog signaling pathway, which is involved in tissue repair. Its development rationale is to inhibit abnormally active repair signals in fibrotic lungs and reduce the continued accumulation of scar tissue. This offers a different therapeutic approach, but the rationale for its mechanism of action still needs to be supported by clinical benefit.

Whether patients also experience improvements in symptoms is an important part of evaluating efficacy. The company said symptom questionnaire results showed numerical improvement, but the trial was not sufficiently powered for statistical testing of this measure. On safety, the company said the incidence of serious adverse events was similar between the treatment and placebo groups. Further data are still needed to clarify the full range of event types, treatment discontinuations, and long-term tolerability.

Endeavor plans to present the data at a medical meeting and discuss a Phase 3 trial with regulators. The findings announced so far are preliminary results provided by the company, and independent information on the same event is not yet available for cross-checking. The key next steps are to establish whether the improvements can be sustained, which patients benefit, and whether changes in lung function and imaging can translate into better daily life and long-term disease control.

References

  1. Endeavor BioMedicines